NEWTON, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- Dynasil Corporation of America DYSL, a developer and manufacturer of optics and photonics products, optical detection and analysis technology and components for the homeland security, medical and industrial markets, today announced second quarter fiscal 2019 results.
Second Quarter Fiscal 2019 Results
Consolidated revenue was $11.5 million for the three months ended March 31, 2019. This $1.2 million or 12% revenue increase resulted from both a 5% increase in Optics segment revenue and a 22% increase in Innovations and Development segment revenue each as compared to the quarter ended March 31, 2018.
Gross profit for the quarter ended March 31, 2019 was $4.4 million, or 38% of revenue, as compared to the gross profit of $3.9 million, or 38% of revenue for the quarter ended March 31, 2018.
Total operating expenses were $4.0 million for the three-month period ended March 31, 2019, a 3% increase over the $3.9 million in operating expenses for the three months ended March 31, 2018. The increase was attributable to our continued investments in our new initiatives, including promotional activities from our new marketing team along with higher patent and recruiting expenses.
Income from operations for the quarter ended March 31, 2019 was $0.3 million, compared with $0.1 million for the quarter ended March 31, 2018.
Certain key metrics by segment for the current quarter and the same quarter last year are presented below:
| Results of Operations for the Three Months Ended March 31, 2019 | |||||||||||||
| Optics | Innovation and Development* | Biomedical | Total | ||||||||||
| Revenue | $ | 6,226,000 | $ | 5,306,000 | $ | - | $ | 11,532,000 | |||||
| Gross profit | 2,159,000 | 2,199,000 | - | 4,358,000 | |||||||||
| GM % | 35% | 41% | - | 38% | |||||||||
| Operating expenses | 1,871,000 | 2,141,000 | 22,000 | 4,034,000 | |||||||||
| Operating income (loss) | $ | 288,000 | $ | 58,000 | $ | (22,000 | ) | $ | 324,000 | ||||
| Results of Operations for the Three Months Ended March 31, 2018 | |||||||||||||
| Optics | Innovation and Development* | Biomedical | Total | ||||||||||
| Revenue | $ | 5,910,000 | $ | 4,345,000 | $ | - | $ | 10,255,000 | |||||
| Gross profit | 2,050,000 | 1,895,000 | - | 3,945,000 | |||||||||
| GM % | 35% | 44% | - | 38% | |||||||||
| Operating expenses | 1,858,000 | 1,813,000 | 194,000 | 3,865,000 | |||||||||
| Operating income (loss) | $ | 192,000 | $ | 82,000 | $ | (194,000 | ) | $ | 80,000 | ||||
| *Formerly Contract Research | |||||||||||||
Net income for the three months ended March 31, 2019 was essentially breakeven, or $0.00 in basic earnings per share, compared to $1.3 million, or $0.08 in basic earnings per share, for the quarter ended March 31, 2018. The provision for income taxes for the second quarter of 2019 was approximately $0.2 million, whereas, during the quarter ended March 31, 2018, the Company had a tax provision benefit of $1.3 million primarily as the result of the estimate of the PATH 2015 R&E Tax Credit for the years 2012 thru 2016 that the Company was in the process of conducting in fiscal year 2018.
Plan to Deregister and Delist the Common Stock
On May 2, 2019, the Company announced that a Special Committee of independent directors has recommended, and its Board of Directors has approved, a plan to cease the registration of the Company's common stock under the federal securities laws following the completion of a proposed reverse stock split transaction and to delist its shares of common stock from trading on the Nasdaq Capital Market. It is expected that this plan would be effectuated in late summer 2019, subject to Dynasil's stockholders approving the proposed reverse stock split at a Special Meeting of Stockholders to be held for that purpose. The Company expects to file a preliminary proxy statement with the SEC later in May. Once available, the Company encourages investors to read the proxy statement.
As the Company is currently in a proxy filing process with respect to the above announcement, it will not be hosting a quarterly conference call with respect to its second quarter fiscal 2019 results.
About Dynasil
Dynasil Corporation of America DYSL develops and manufactures optics and photonics products, optical detection and analysis technology and optical components for the homeland security, medical and industrial markets. Combining world-class expertise in research and materials science with extensive experience in manufacturing and product development, Dynasil is selling and continuing to develop products for dual-mode radiation detection solutions for security and commercial applications and sensors for non-destructive testing. Dynasil has an impressive and growing portfolio of issued and pending U.S. patents. The Company is based in Newton, Massachusetts, with additional operations in Massachusetts, New Jersey, New York and the United Kingdom. More information about the Company is available at www.dynasil.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding results of operations, our compliance with the financial covenants under our loan agreements with Middlesex Savings Bank and Massachusetts Capital Resource Company, our expectations regarding results of operations, the commercialization of our technology, including the Xcede patch and our dual mode detectors, the success of efforts to develop a successful Xcede Patch and to fund that development, our development of new technologies including at Dynasil Biomedical, the adequacy of our current financing sources to fund our current operations, our growth initiatives, our capital expenditures, the strength of our intellectual property portfolio, perceived benefits and costs of the proposed stock split transaction, the number of shares of the Company's common stock that are expected to be cashed out in the such transaction and the timing and stockholder approval of such transaction.. These forward-looking statements may be identified by the use of words such as "plans," "intends," "may," "could," "expect," "estimate," "anticipate," "continue," or similar terms, though not all forward-looking statements contain such words. The actual results of the future events described in such forward looking statements could differ materially from those stated in such forward looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to develop and commercialize our products, including obtaining regulatory approvals, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, Xcede's ability to produce preclinical data sufficient to enable it to initiate clinical studies of hemostatic patch, clinical results of Xcede's programs which may not support further development, the ability of our RMD business unit to identify and pursue possible continued development opportunities for the Xcede patch, which is not assured, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices to governmental customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to deleverage our balance sheet, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, seasonality, the many variables that may impact the Company's projected cost savings, variables and risks related to consummation of the proposed stock split transaction, SEC regulatory review of the Company's filings related to the such transaction, and the continuing determination of the Board of Directors and Special Committee that such transaction is in the best interests of all stockholders. as well as the uncertainties set forth in the Company's Annual Report on Form 10-K, filed on December 21, 2018, including the risk factors contained in Item 1A, and from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
| Dynasil Corporation of America and Subsidiaries | |||||
| Consolidated Balance Sheets (Unaudited) | |||||
| ASSETS | March 31, 2019 | September 30, 2018 | |||
| Current Assets | |||||
| Cash and cash equivalents | $ | 350,000 | $ | 2,327,000 | |
| Accounts receivable, net | 3,950,000 | 4,069,000 | |||
| Unbilled receivables | 2,553,000 | 1,215,000 | |||
| Contract assets | 19,000 | - | |||
| Inventories, net of reserves | 4,525,000 | 4,106,000 | |||
| Prepaid expenses and other current assets | 847,000 | 664,000 | |||
| Total current assets | 12,244,000 | 12,381,000 | |||
| Property, Plant and Equipment, net | 8,020,000 | 8,098,000 | |||
| Other Assets | |||||
| Intangibles, net | 701,000 | 755,000 | |||
| Deferred tax asset | 4,198,000 | 4,333,000 | |||
| Goodwill | 5,900,000 | 5,900,000 | |||
| Long term contract assets | 26,000 | 7,000 | |||
| Security deposits | 53,000 | 58,000 | |||
| Total other assets | 10,878,000 | 11,053,000 | |||
| Total Assets | $ | 31,142,000 | $ | 31,532,000 | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||
| Current Liabilities | |||||
| Equipment line of credit | $ | 484,000 | $ | - | |
| Current portion of long-term debt | 1,307,000 | 1,246,000 | |||
| Capital lease obligations, current | 33,000 | 40,000 | |||
| Accounts payable | 2,218,000 | 2,355,000 | |||
| Contract liabilities | 25,000 | 253,000 | |||
| Accrued expenses and other liabilities | 2,469,000 | 2,803,000 | |||
| Total current liabilities | 6,536,000 | 6,697,000 | |||
| Long-term Liabilities | |||||
| Long-term debt | 1,660,000 | 2,075,000 | |||
| Long-term capital lease obligations | 38,000 | 52,000 | |||
| Deferred tax liability | 205,000 | 205,000 | |||
| Other long-term liabilities | 180,000 | 175,000 | |||
| Total long-term liabilities | 2,083,000 | 2,507,000 | |||
| Stockholders' Equity | |||||
| Dynasil stockholders' equity | 21,249,000 | 21,029,000 | |||
| Noncontrolling interest | 1,274,000 | 1,299,000 | |||
| Total stockholders' equity | 22,523,000 | 22,328,000 | |||
| Total Liabilities and Stockholders' Equity | $ | 31,142,000 | $ | 31,532,000 | |
Dynasil Corporation of America
Consolidated Statement of Operations and Comprehensive Income (Loss)
(Unaudited)
| Three Months Ended | Six Months Ended | |||||||||||||
| March 31, | March 31, | |||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||
| Net revenue | $ | 11,532,000 | $ | 10,255,000 | $ | 21,560,000 | $ | 19,443,000 | ||||||
| Cost of revenue | 7,174,000 | 6,310,000 | 13,510,000 | 11,958,000 | ||||||||||
| Gross profit | 4,358,000 | 3,945,000 | 8,050,000 | 7,485,000 | ||||||||||
| Operating expenses: | ||||||||||||||
| Sales and marketing | 477,000 | 388,000 | 875,000 | 667,000 | ||||||||||
| Research and development | 147,000 | 215,000 | 324,000 | 524,000 | ||||||||||
| General and administrative | 3,410,000 | 3,262,000 | 6,652,000 | 6,418,000 | ||||||||||
| Total operating expenses | 4,034,000 | 3,865,000 | 7,851,000 | 7,609,000 | ||||||||||
| Income (loss) from operations | 324,000 | 80,000 | 199,000 | (124,000 | ) | |||||||||
| Interest expense, net | 46,000 | 45,000 | 88,000 | 88,000 | ||||||||||
| Income (loss) before taxes | 278,000 | 35,000 | 111,000 | (212,000 | ) | |||||||||
| Income tax (benefit) | 206,000 | (1,255,000 | ) | 141,000 | (595,000 | ) | ||||||||
| Net income (loss) | 72,000 | 1,290,000 | (30,000 | ) | 383,000 | |||||||||
| Less: Net loss attributable to noncontrolling interest | (4,000 | ) | (33,000 | ) | (13,000 | ) | (108,000 | ) | ||||||
| Net income (loss) attributable to common stockholders | $ | 76,000 | $ | 1,323,000 | $ | (17,000 | ) | $ | 491,000 | |||||
| Net income (loss) | $ | 72,000 | $ | 1,290,000 | $ | (30,000 | ) | $ | 383,000 | |||||
| Other comprehensive income (loss): | ||||||||||||||
| Foreign currency translation | 145,000 | 222,000 | 4,000 | 257,000 | ||||||||||
| Total comprehensive income (loss) | 217,000 | 1,512,000 | (26,000 | ) | 640,000 | |||||||||
| Less: comprehensive income (loss) | ||||||||||||||
| attributable to noncontrolling interest | (4,000 | ) | (33,000 | ) | (13,000 | ) | (108,000 | ) | ||||||
| Total comprehensive income (loss) | ||||||||||||||
| attributable to common stockholders | $ | 221,000 | $ | 1,545,000 | $ | (13,000 | ) | $ | 748,000 | |||||
| Basic net income (loss) per common share | $ | 0.00 | $ | 0.08 | $ | (0.00 | ) | $ | 0.03 | |||||
| Diluted net income (loss) per common share | $ | 0.00 | $ | 0.08 | $ | (0.00 | ) | $ | 0.03 | |||||
| Weighted average shares outstanding | ||||||||||||||
| Basic | 17,433,249 | 17,133,468 | 17,379,113 | 17,090,530 | ||||||||||
| Diluted | 17,433,249 | 17,133,468 | 17,379,113 | 17,090,530 | ||||||||||
Contact:
Patty Kehe
Corporate Secretary
Dynasil Corporation of America
Phone: 617.668.6855
pkehe@dynasil.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
